Goldberg Law PC (the “Firm”) announces a class action lawsuit has been filed against Seres Therapeutics, Inc. (“Seres” or the “Company”) (Nasdaq: MCRB). Investors who purchased or otherwise acquired shares between June 25, 2015 and July 29, 2016 (the “Class Period”) are encouraged to contact the Firm in advance of the November 28, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, Seres made materially false and misleading statements and/or failed to disclose material facts about its lead drug product candidate SER-109, touting its potential and efficacy. On July 29, 2016, the Company announced that the Phase 2 clinical trial of SER-109 did not meet its primary endpoint. When this news was released, shares of Seres fell in value, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161003006217/en/